Novartis to Acquire Avidity Biosciences in a Landmark $12 Billion Transaction

Global pharmaceutical powerhouse Novartis has revealed plans to acquire biotechnology company Avidity Biosciences for an estimated $12 billion. This strategic move underscores Novartis’s commitment to broadening its RNA-based therapy portfolio,notably in the realm of genetic medicine.

Key Terms of the Acquisition Deal

Under the terms of the agreement, Novartis will offer Avidity shareholders $72 per share in cash, which represents a 46% premium over Avidity’s closing price last Friday. The deal is expected to close within the first half of 2026, contingent upon Avidity divesting certain assets including early-stage precision cardiology programs.

Pioneering RNA Therapeutics Targeting Muscle Disorders

Avidity Biosciences focuses on antibody-oligonucleotide conjugates (AOCs), a cutting-edge class of RNA therapeutics engineered to selectively target muscle tissue. These therapies work by altering gene expression at its source and hold notable potential for treating complex muscular diseases that have been historically challenging to address.

“Avidity’s innovative delivery platforms for muscle-targeted RNA treatments represent a breakthrough,” stated Novartis CEO Vas Narasimhan. “We look forward to accelerating these programs and delivering transformative benefits for patients.”

Boosting Growth Forecasts and expanding Research Infrastructure

This acquisition has led Novartis to revise upward its compound annual growth rate (CAGR) forecast from 5% to 6% over the period from 2024 through 2029. Concurrently, Novartis is investing approximately $23 billion into expanding its U.S.-based research infrastructure,including launching a second R&D hub in San Diego aimed at fostering innovation across multiple therapeutic areas.

Collaborative Efforts Enhancing Cardiovascular and Renal Disease Pipelines

Along with acquiring Avidity,Novartis recently forged partnerships with Anthos Therapeutics and Regulus Therapeutics focused on advancing treatments for cardiovascular and kidney diseases. These alliances complement their broader strategy of diversifying treatment options across various high-need medical fields.

Market Activity Prior To Completion

• avidity shares closed last Friday at $49.15-an notable gain nearing 70% since January-resulting in an approximate market capitalization of $7.2 billion.
• The stock price for Novartis ended trading last Friday at $130.36 per share.